Create your Watchlist to save your favorite quotes on Nasdaq.com. Illumina to Acquire GRAIL Launching a New Era in Cancer Detection September 21, 2020. A startup focused on early detection of cancer that was spun out of one of the largest genetic analysis companies three years ago is now being acquired by the latter. Grail acquired by Illumina. Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, announced that they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. Subscribe to the Crunchbase Daily. 858.291.6421 ir@illumina.com Sign up for free newsletters and get more CNBC delivered to your inbox. Gene sequencing firm Illumina announced plans on Monday to buy cancer screening startup Grail in a cash-and-stock deal worth $8 billion.. Well, Grail’s initial public offering (IPO) isn’t going to happen. Illumina is Grail's largest shareholder, holding a 14.5% stake. GRAIL will receive $3.5 billion in cash and $4.5 billion in Illumina stock, and the deal will pave the way for Illumina to lead the cancer screening and detection industry. 2 Additional Information and Where to Find It. Illumina currently holds 14.5 percent of GRAIL's shares outstanding and about 12 percent on a fully diluted basis. After concluding the transaction, expected in the second half of 2021, GRAIL will operate as a standalone division within Illumina. Biotechnology company Illumina has signed a definitive agreement to acquire multi-cancer blood test developer Grail for cash and stock consideration of $8bn. SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. @/i, failureMessage: "A valid email address is required", negate: "true"});var dom2 = document.querySelector('#form1783 #field2');var field2 = new LiveValidation(dom2, {validMessage: "", onlyOnBlur: false, wait: 300});field2.add(Validate.Presence, {failureMessage:"This field is required"});var dom5 = document.querySelector('#form1783 #field5');var field5 = new LiveValidation(dom5, {validMessage: "", onlyOnBlur: false, wait: 300});field5.add(Validate.Custom, {against: function(value) {return !value.match(/(telnet|ftp|https?):\/\/(?:[a-z0-9][a-z0-9-]{0,61}[a-z0-9]\.|[a-z0-9]\. Overview. Illumina founded GRAIL in 2016 and later spun out it to develop state-of-the-art data science, ML and create the atlas of cancer signals in the blood, enabling multi-cancer early detection tests Acquired Organization: Grail Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Rather than going public as planned, early cancer detection company Grail chose to be acquired by Illumina in a deal that will provide immediate returns to the outside investors that backed its spinout while allowing them to participate in the company’s upside as Illumina currently holds 14.5 percent of GRAIL… This … GRAIL stockholders excluding Illumina will receive approximately 9.9 million Illumina shares if the 20-trading-day volume weighted average price of Illumina … RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. Illumina said on Monday it would buy cancer screening startup Grail in a cash-and-stock deal worth $8 billion, buying out investors including Jeff Bezos and snatching back a business it hived off four years ago as a separate company. ] Grail is set to be acquired for $8 billion by Illumina, the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years ago. Screenshot of GRAIL's website ... San Diego-based Illumina, which founded GRAIL in … The price: $3.5 billion in cash and $4.5 billion in shares of Illumina … Non-controlling interest is the portion of net loss associated with Helix and GRAIL that is not attributable to the Illumina shareholders 2016 Revenue1 +16% YoY1 EPS3 $3.55 – $3.65 node.dataset.value : node.getAttribute('data-value'); if (selectedValue) { for (var j = 0; j < node.options.length; j++) { if(node.options[j].value === selectedValue) { node.options[j].selected = 'selected';break;}}}}}, Nasdaq Boardvantage Board Portal Software, Do Not Sell My Personal Information (CA Residents Only). Grail (Nasdaq: GRAL) was founded in 2016 by San Diego-based Illumina as a separate company and had raised about $2 billion, with investors including Amazon’s Jeff Bezos and Microsoft co-founder Bill Gates. 3. Cancer detection startup Grail will be acquired by DNA sequencing machine maker Illumina for $8 billion in cash and stock, the companies announced Monday. Illumina To Acquire GRAIL In $8 Bln Cash, Stock Deal . In addition, Grail shareholders will receive future payments tied to certain Grail-related revenues. Most liquid biopsies use next-generation sequencing to scan blood samples for fragments of tumor DNA in people previously diagnosed with cancer. Illumina says it will acquire the remaining stake in Jeff Bezos-backed gene-sequencing company Grail that it doesn’t already own for $8 billion in cash and stock. GRAIL was founded by Illumina in 2016 and is now backed by Amazon founder Jeff Bezos and billionaire Bill Gates. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. To understand this deal, recent events and the investment thesis, I go back to the start of 2017 when I last covered the shares, and to gain some perspective. The transaction is expected to add to to Illumina revenue starting in 2021. To understand this deal, recent events and the investment thesis, I go back to the start of 2017 when I last covered the shares, and to gain some perspective. Illumina Inc., San Diego, and Grail, Menlo Park, Calif, a healthcare company whose mission is focused on multi-cancer early detection, announced they have entered into a definitive agreement under which Illumina will acquire Grail for cash and stock consideration of … GRAIL comes back into the Illumina fold after it was spun out as a standalone company in January 2017. Data is a real-time snapshot *Data is delayed at least 15 minutes. The rumors are indeed true – Illumina is attempting to acquire early cancer detection specialist Grail for about $8 billion. The rumors are indeed true – Illumina is attempting to acquire early cancer detection specialist Grail for about $8 billion. Cancer detection startup Grail will be acquired by DNA sequencing machine maker Illumina for $8 billion in cash and stock, the companies announced Monday. Grail stockholders will also receive future payments based on Grail-related revenue. Save. Acquired Organization: Grail Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Illumina To Acquire GRAIL In $8 Bln Cash, Stock Deal, Palantir’s Covid-19 Contract With US Government Under Threat – Report, Weekly Preview: Earnings To Watch This Week (IBM, INTC, NFLX, UAL), What To Do if You Haven't Received Your $600 Stimulus Check, In The Money: The Pandemic, Consumer Confidence, And Debt [Recorded 1/20/21], German Green Chief Hails Biden's Planned Return to Paris Accord, #TradeTalks: A form of volatility control that monitors and reacts intraday to market volatility, WEF Sees Disease, Climate as Top Global Risks for 2021, Daily Markets: Earnings Season Kicks Off; President-Elect Biden Releases Covid Relief Plan, 2 COVID Vaccine Stocks That Could Trounce Pfizer and Moderna in 2021, 3 5G Stocks That Could Benefit From the Next Revolution in Tech, var dom1 = document.querySelector('#form1783 #field1');var field1 = new LiveValidation(dom1, {validMessage: "", onlyOnBlur: false, wait: 300});field1.add(Validate.Presence, {failureMessage:"This field is required"});field1.add(Validate.Format, {pattern: /(^[A-Z0-9!#$%&'\*\+\-\/=\?\^_`\{\|\}~][A-Z0-9!#$%&'\*\+\-\/=\?\^_`\{\|\}~\.]{0,62}@(([A-Z0-9](?:[A-Z0-9\-]{0,61}[A-Z0-9])?)(\.[A-Z0-9](?:[A-Z0-9\-]{0,61}[A-Z0-9])? lllumina Investor Relations 5200 Illumina Way San Diego, CA 92122. The agreement has been approved by the Boards of Directors of Illumina and GRAIL. Illumina, and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. An earlier version of Galleri was able to detect more than 50 cancer types, over 45 of which have no recommended screenings in the U.S. Cancer is one of society's most significant challenges, with most cancer being detected too late. Grail was established as an independent company back in 2016, with a majority stake held by Illumina. Following its $8 billion pitch last year to acquire Grail and its upcoming multi-tumor blood test, Illumina is planning a deeper dive into cancer genomics with a … Illumina to Acquire Cancer Diagnostics Start-up Grail ... Grail was founded by Illumina in 2016, spun off as an independent company, and has raised $1.9 billion in four rounds of private equity. Analysts peg the market for liquid biopsies in the range of least $30 billion to $130 billion in the United States alone. The company set a deadline of December 20th for consummating the acquisition, at which point Illumina will begin offering Grail $35 million per month in cash payments until the deal closes. Illumina (NASDAQ: ILMN), which develops, manufactures, and markets integrated systems for DNA analysis, agreed to acquire GRAIL in a deal worth worth $8 billion. Illumina will acquire Grail, an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock (see story).Before Grail was acquired by Illumina, Grail merged with Cirina, a Hong Kong company that had developed the novel technology that was the cornerstone for Grail's cancer test (see story). McKesson Ventures is a venture capital fund that invests in companies addressing business challenges facing the health care industry. Illumina to Acquire GRAIL to Launch New Era of Cancer Detection Illumina (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for … This includes $3.5 billion in cash and $4.5 billion in shares of Illumina common stock. Behind Grail, Illumina’s billion-dollar diagnostics startup ... By the time Illumina acquired Verinata, the prenatal test had been run over 100,000 times, Huber said. Prior to GRAIL, Aravanis served as Senior Director of R&D for Illumina, Inc., where he developed multiple technologies, including clinical assays for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics, and liquid biopsy using cell-free nucleic acids. In September 2020, Illumina announced a proposed cash and stock deal to acquire Grail for $8 billion. Illumina originally spun off Grail in early 2017. The total NGS oncology testing addressable market is expected to grow at a CAGR of 27% to $75 billion in 2035. Overview. Summary. Deals and Financings. But shares of Illumina were down 8.4% at $270.80, as some questioned the rationale. Illumina stockholders are expected to own approximately 93 percent of the combined company, while GRAIL stockholders will own approximately 7 percent. After hitting a peak at $220 in 2015, shares had … The deal comes weeks after Grail filed to go public. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Gene sequencing firm Illumina announced today the acquisition of Grail, a company focused on multi-cancer early detection, for $8 billion. Grail acquired by Illumina. General Inquiries. Acquiring Organization: Illumina Illumina is an innovative technology and revolutionary assays aiming the … All Rights Reserved. Shots: Illumina to acquire GRAIL in cash & stock transaction for $8B including ~$3.5B in cash and $4.5B in shares of Illumina common stock. GRAIL: Cancer screening startup GRAIL to be acquired by Illumina Illumina and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. Illumina’s eight billion-dollar acquisition of GRAIL is a landmark deal in the biotechnology space. Sep. 21, 2020, 07:00 AM. S1 form (Sep-2020) ... Acquired Participants: Illumina. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Grail was founded by Illumina as a separate company in 2016 and had raised about $2 billion, with investors including Bezos and Microsoft co-founder Bill Gates. After hitting a peak at $220 in 2015, shares had fallen to $140 at the start of 2017. GRAIL, which plans 400 jobs in RTP, is being acquired in $8B deal. I would like to receive Nasdaq communications related to Products, Industry News and Events.You can always change your preferences or unsubscribe and your contact information is covered by our Privacy Policy. "We don't see the clear fit for acquiring a company that is still at a stage where clinical studies and clinical product development are still critical and will be for years," Cowen analyst Doug Schenkel said in a client note. It will also help transform cancer care using genomics and Illumina's Next-Generation Sequencing (NGS) platform. We want to hear from you. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. List of Illumina 's 15 Acquisitions, including Grail and Enancio Save Search Companies People Investors Funding Rounds Acquisitions Schools Events Hubs Saved Illumina to Buy Gates, Bezos-Backed Grail in $8 Billion Deal Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. Illumina is rumoured to be in talks with oncology testing company Grail over a potential $8bn bid. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Grail plans to launch its test for early detection of cancers, Galleri, next year. Grail was founded by Illumina as a separate company in 2016 and had raised about $2 billion, with investors including Bezos and Microsoft co-founder Bill Gates. © 2021 CNBC LLC. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? These symbols will be available throughout the site during your session. Time to update the investment thesis on Illumina after it acquired GRAIL . The purchase in cash and stock of Grail, a developer of a long-sought blood test that promises to detect cancer early, will be Illumina’s biggest acquisition. (RTTNews) - Biotech company Illumina Inc. (ILMN) agreed to buy healthcare company GRAIL, Inc. in a cash and stock deal valued at $8 billion. GRAIL stockholders will also receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. At GRAIL, we find purpose in ... Illumina in Talks to Buy Grail, Possibly for Over $8 Billion (Sep-2020) Source: www.thestreet.com. Illumina will get access to Grail's "liquid biopsy" blood test, Galleri, which helps identify early-stage cancers and is expected to be launched commercially in 2021, betting on a market that is expected to grow rapidly in coming years. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. )+[a-z]{2,63}/i);}, failureMessage: "Value must not contain any URL's"});field5.add(Validate.Presence, {failureMessage:"This field is required"});field5.add(Validate.Length, {tooShortMessage:"Invalid length for field value", tooLongMessage: "Invalid length for field value", minimum: 4, maximum: 4});function handleFormSubmit(ele) { var submitButton = ele.querySelector('input[type=submit]'); var spinner = document.createElement('span'); spinner.setAttribute('class', 'loader'); submitButton.setAttribute('disabled', true); submitButton.style.cursor = 'wait'; submitButton.parentNode.appendChild(spinner); return true; }function resetSubmitButton(e){ var submitButtons = e.target.form.getElementsByClassName('submit-button'); for(var i=0;i